the last follow-up, 20 patients are still alive with initial diagnosis of LD (n=8), CML (n=5), MM (n=2), AL+MDS (n=5), and prior conditioning 7 patients (35%) were in progressive disease. Among these 20 alive patients, 16 (80%) presented a chronic GVHD (7 limited and 8 extensive) of whom 12 (75%) have received PBSC as HSC source and 16 patients (80%) are in continuous complete remission (14 among them presented a cGVHD). Regarding cGVHD incidence, we observed a trend in favour of ATG during conditioning [19/44 (43%) cGVHD with ATG vs 11/15 (73%) without ATG (p=0.08)] and a protective effect of cGVHD on event-free survival [HR=0.34 (CI 0.17-0.70) p=0.003]. This study demonstrates the existence of long-term survivors in continuous CR after allogeneic non myeloablative HSC transplantations with high rate of cGVHD and illustrates the need of future prospective trials for GVHD prophylaxis within this context.
Oral Session: Graft versus host disease / Tolerance and rejection
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Depletion of MLC-activated CD69+ cells combined with CTLA4-Ig treatment as a strategy to control T-cell mediated alloreactivity R. Maccario, A. Cometa, A. Moretta, P. Comoli, D. Montagna, M.A. Avanzini, M. Labirio, G. Giorgiani, M. Zecca, F. Locatelli (Pavia, I) Aim of the study is to investigate new strategies of ex vivo manipulation of alloantigen-specific immune response, to obtain populations of cells substantially and selectively devoid of alloreactivity and, therefore, apt to be employed for accelerating immune reconstitution after T cell depleted HSCT, without augmenting the risk of GVHD. To this end, PBMC of a responder individual were cultured with irradiated stimulator PBMC of an unrelated, HLA-diverse subject. After 72-hour culture, CD69+ cells, including both CD4+ and CD8+ T lymphocytes, were depleted from MLC. CD69-depleted populations, together with fresh stimulator PBMC were then cultured for further 12 days in the presence of CTLA4-Ig (treated MLC). Cell recovery of treated-MLC was 25-30% of that obtained from control (ctrl) MLC. Effector cells recovered from treated and ctrl MLC were tested in secondary MLC, in the absence of CTLA4-Ig. Results of secondary MLC, obtained from 2 experiments, demonstrated that: 1) proliferative activity (+3 and +7 day-culture) of effector cells obtained from treated MLC, was absent or very low, if compared with effector cells of ctrl MLC; 2) cytotoxic activity directed towards allogeneic stimulator target cells, measured after 10-day culture in the presence of exogenous IL-2 (5 U/ml at day +3 and +6), was undetectable for treated MLC and ranged between 35-50% of specific lysis for ctrl MLC; 3) capacity to produce cytokines (measured by 48-hour ELISPOT), particularly IFN-gamma and IL-12, was substantial in ctrl MLC and absent in treated MLC. Other cytokines (IL-2, IL-4, IL-5, IL-10) were comparably low in both conditions. Cell recovered from treated MLC after 10-day secondary MLC in the presence of added IL-2 included a high percentage (> 70%) of CD4+CD25+ lymphocytes, most expressing CTLA4, while this subset was < 40% in ctrl MLC with a minority expressing CTLA4. Altogether, these preliminary data suggest that effectors from treated MLC are strongly depleted in alloreactive cytotoxic cells, while they are enriched in a subset of CD4+CD25+ cells, recently described to display regulatory/suppressive function of immune response. Experiments are in progress to define the immunocompetence of effector cells obtained from treated MLC towards antigens other than alloantigens (e.g. microbial antigens), and to investigate the possibility that selected stimuli, such as virus antigens might reverse the state of alloantigen-specific unresponsiveness.
O378
Microscopic chimerism in lymphatic organs persists after vascularized bone marrow transplantation Z. Akdogan, F. Quatra, R. De Jesus, D. Lowenberg, L.A. BaxterLowe, D. Brooks, H. Buncke (San Francisco, USA) Vascularized bone marrow transplantation has been attempted in recent times suggesting that transplantation of hematopoietic stem cells with their own microenviroment may lead to better results. Research has mainly focused on the rate and speed of repopulation in bone marrow depleted recipients or on the induction of chimerism in association with different immunosuppressive agents. Our objectives were to evaluate the early events associated with rejection of a vascularized bone marrow transplant including any transient condition of chimerism in the peripheral blood or in the lymphatic organs of the recipients. Methods: Lewis rat recipients received vascularized (femur) and non-vascularized bone marrow transplants and/or vascularized/nonvascularized thymus transplants from Brown Norway recipients. Blood was subsequently drawn at scheduled intervals to be processed for double staining with a TcRalpha/beta monoclonal antibody PE-conjugated (R73) and an MHC-I donor specific monoclonal antibody FITC-conjugated (RT1-Ac) for assessment of hematopoietic chimerism. Previous studies at our institution showed that immunohistochemistry is a sensitive mean to study microchimerism in the thymus and spleen, with the addition of a morphological picture of ongoing interactions between donor-derived cells in the host environment. Frozen sections of thymus and spleen were therefore harvested and processed for staining with the biothinilated donor-specific antibody (RT1-Ac). Results: Although hematopoietic chimerism in the peripheral blood quickly disappeared with ongoing rejection in all the experimental groups, however under certain conditions donorderived cells persisted in the lymphatic organs and survived well beyond complete rejection of the vascularized femur/thymus transplant. Conclusion: Prolonged survival of donor-derived cells without immunosuppressive treatment suggests a form of dynamic balance in the interaction between host and recipient of a vascularized bone marrow transplant. It is possible that rapid recovery of the transplant with almost-immediate return of function may help overcoming host reactions allowing a limited number of cells to survive. Further characterization of the cell populations involved is underway and could help understand the frequent occurrence of tolerance in rat models of vascularized bone marrow/limb transplantation.
O379
Purified donor KN-cell infusion to revert impending rejection after haplo-identical stem cell tansplantation J. Passweg, D. Tsakiris, S. Meyer-Monard, A. Buser, D. Heim, A. Gratwohl, A. Tichelli (Basel, CH) Donor lymphocyte infusions may be used to treat relapse in improve engraftment but these are usually avoided after haploidentical SCT because of GvHD risks. Recent experimental data have shown, that alloreactive NK cells may promote engraftment without causing GvHD. A 25 year old female patient received a haploidentical stem cell transplant to treat a first refractory relapse of AML M4 treated initially with chemotherapy and autologous SCT. Conditioning was with VP-16, cyclophosphamide, TBI and ATG, posttransplant immunosuppression consisted of a 14 day course of cyclosporine and a 10 day course of OKT3 to promote engraftment. She received 35 x 10e6/kg highly purified CD34+ cells (0.55 x 10e5/kg CD3+cells) from her haplo-identical father. The HLA typing (patient: HLA Cw07, Cwx; donor: HLA Cw07, Cw04) was indicaive of NK-cell alloreactivity between donor and recipient. She engrafted well and the posttransplant course was uncomplicated. 2 months posttransplant she had normal blood counts with complete chimerism as measured by whole blood STR-PCR. At 3 months posttransplant there were signs of impending rejection with 21% of recipient alleles. She then received 1.41 x 10e7/kg NK-cells (CD56 positive and CD3 negatively selected using the Clinimacs device) T-cell depleted to 0,1 x 10e5/kg CD3+ cells. This NK-cell infusion was well tolerated and resulted in some temporary diffuse skin swelling. Skin GvHD as a cause of this reaction could not be ruled out but was not confirmed by skin biopsy. A second NK-cell infusion was given 3 months later. She is now 6 months after the first NK-cell infusion and 9 months after transplant in complete remission with normal blood counts and with >95% donor type chimerism. This case illustrates, that haploidentical NK-cells may be given without induction of acute GvHD and may revert impending rejection.
O380
Human mesenchymal stem cells inhibit development of cytotoxic lymphocytes and differentiation of dendritic cells induced by mixed lymphocyte reaction R. Maccario, A. Moretta, M. Podestà, A. Cometa, G. Piaggio, D. Montagna, P. Comoli, D. Lisini, F. Bonetti, F. Frassoni, F. Locatelli (Pavia, Genoa, I) Recent studies have demonstrated the capacity of human mesenchymal stem cells (hMSC) to suppress T-cell proliferation induced in vitro by mitogens or allogeneic stimulus and to reduce GVHD when co-infused with HLA-identical HSC transplant. Aims of the study were to evaluate the dose-dependent immunomodulatory effect of addition of non-irradiated hMSC to a MLC and to investigate the potential synergistic action of hMSC and cyclosporin-A (CsA) in suppressing alloantigen-specific lymphocyte activation. Third-party hMSC were added to one-way primary MLC, set-up with unrelated HLA-mismatched responder/stimulator (R/S) donor pairs, at 3 different R's PBMC/hMSC ratios: 1/1, 10/1, 100/1. Dendritic cell (DC) differentiation, kinetics of NK and T-cell subset expansion, and cytotoxic activity towards allogeneic and hMSC targets were evaluated after both primary and secondary MLC. Results showed that addition of hMSC to the primary MLC strongly inhibited, at all 3 R's PBMC/hMSC ratios, the alloantigen-induced DC differentiation. and caused a dose-dependent suppression of MLC-induced proliferating and expanding capacity o f both NK and T cell subsets. The inhibitory effect was more striking on CD8+ T lymphocytes and on CD3neg/CD56+ NK cells than on CD4+ T lymphocytes. During secondary MLC, culture conditions initially set-up at R's PBMC/hMSC ratios of 10/1 and 100/1 showed a partial (CD8+) or complete (CD4+) recovery of both proliferating and expanding capacity of T cell subsets in comparison with control (ctrl) MLC, while NK cells did not recover. In MLC initially set-up at R's PBMC/hMSC ratios of 1/1, proliferating and expanding capacity of NK cells, CD4+ and CD8+ T lymphocytes was very low both in primary and secondary MLC. Cytotoxic activity of effector cells, recovered from both primary and secondary MLC and directed towards the allogeneic target, was absent in culture conditions set-up at R's PBMC/hMSC ratios of 1/1 and comparable to that of ctrlMLC in culture conditions set-up at R's PBMC/hMSC ratios of 1/10 or 1/100. Cytotoxic activity towards hMSC was absent in all culture conditions. Co-addition of 100 ng/ml of CsA to primary MLC exerted a synergistic effect with hMSC leading to a complete inhibition of cytototoxic activity towards allogeneic target cells, both in primary and secondary MLC, at all 3 R's PBMC/hMSC ratios. Further experiments will better define the mechanisms underlying the suppressive effect exerted by hMSC on lymphocyte activation in the presence of CsA.
O381
TNF alpha promoter polymorphisms have a significant impact on engraftment in unrelated donor hematopoietic stem cell transplant B.E. Shaw, C. Smith, M.N. Potter, N.P. Mayor, S.G.E. Marsh, J.A. Madrigal (London, UK) Tumour necrosis factor alpha (TNFA) has been shown to play a critical role in the outcome of haematopoietic stem cell transplants (HSCT). The TNF alpha gene lies in the so called 'class III' region of the MHC on chromosome six, close to other genes for factors important in the immune system, and between the polymorphic HLA class I and II regions. A number of polymorphisms have been described in the TNFA gene. There are two polymorphic positions in the TNFA promoter; -308 (G/A) and -238 (G/A). The polymorphism at position -308 has been extensively studied, and the rarer 'A" allele has been shown not only to be associated with an increase in the production of TNFA (through an influence on t ranscriptional activity), but also to have disease associations and impact on the occurrance of post-transplant complications in sibling donor HSCT. There are no published data considering the impact of the polymorphism at position -238. We have typed, by RSCA, the TNFA alleles in 189 donor/recipients pairs, all of whom have allele level typing for HLA-A,-B,-C,-DRB1,-DQB1,-DPB1. The 1G allele (G-G) was most common, 73%, 2G (A-G) less common, 22% and the 1A allele (G-A) very rare, 4% (similar frequencies in both recipient and donor populations). 125 pairs were matched for HLA-A,-B,-C,-DRB1,-DQB1. Despite this we found that 8% of the pairs did not match for both TNFA alleles, confirming the presence of relatively common recombinations in this region. Failure to achieve sustained myeloid engraftment is associated with increased morbidity and mortality in unrelated donor HSCT. We analysed engraftment in this heterogenous cohort of T cell depleted transplant pairs, and noted a decrease in the rate of neutrophil engraftment in donors homozygous for the 2G allele (2G heterozygous vs 2G homozygous vs 2G absent; 100% vs 80% vs 93% chi2 test: p=0.059) In addition, when we examined engraftment as a time variable using Kaplan-Meier methods, there was a significant delay in engraftment in those donors possessing a 2G allele (log rank: p=0.035). The effect in recipients was similar, though less marked. Thus, it appears that in an unrelated donor transplant setting, engraftment is influenced by the polymorphisms in the TNFA promoter. The impact and biological significance of the polymorphism at position -238 requires further investigation, as do other transplant complications.
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Antithymocytoglobulin as prophylaxis of graft failure and graft-versus-host disease in recipients of partially T-cell depleted grafts from matched unrelated donors: a dosefinding study E. Meijer, J. Cornelissen, B. Lowenberg, L. Verdonck (Utrecht, Rotterdam, NL) Despite improvements in HLA typing, graft-versus-host disease (GVHD) is still a major cause of morbidity and mortality after stem cell transplantation (SCT) with grafts from matched unrelated donors (MUDs). T cell depletion (TCD) of grafts is an effective method for prevention of GVHD. One of the limitations associated with TCD of grafts is the occurrence of graft failure. Varying strategies are used to prevent graft failure, which is considered to be mediated by residual host T cells having survived the conditioning regimen. A method commonly used in the setting of SCT with TCD grafts from MUDs, is the in vivo pretransplant depletion of host immune cells using Antithymocyteglobulin (ATG) or Campath-1. Several reports also showed effectiveness of in vivo TCD, using ATG or Campath-1, as prophylaxis of GVHD after MUD transplantation. The optimal dose of ATG with respect to prevention of graft failure and severe GVHD is not known. The immunosuppressive and direct toxic effects of ATG, however, necessitate the use of the lowest possible dose. In this study, we set out to evaluate the effect of 3 different ATG(Thymoglobulin™)doses on graft failure and incidence of acute GVHD among recipients of partially TCD grafts from MUDs. Data of 74 consecutively treated patients were analysed. Fifty-two, 13 and 9 patients were treated with ATG, which was given pre-transplant, in a total dose of 8 mg/kg, 6 mg/kg and 4 mg/kg (given in 4 days), respectively. Granulocyte and platelet engraftment was not different between the groups, while graft failure was observed in two patients only (receiving 8 mg/kg and 4 mg/kg ATG, respectively. The incidence of severe acute GVHD (grade III-IV) was 4%, 0% and 56% in groups receiving 8 mg/kg ATG, 6 mg/kg and 4 mg/kg, respectively (p<0.001). After univariate analyses, no impact of other known risk factors (older age, high-risk disease status, CD3+ and CD34+ cell counts in grafts, positive recipient CMV serostatus, male recipient with female donor) for occurrence of acute GVHD was found. Based on these findings, we recommend when ATG is used in the setting of SCT with (partially) TCD grafts from MUDs, to give a total dose of 6-8 mg/kg. A further decrease in dosage resulted in a highly significant increase in incidence of severe acute GVHD.
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The early reduction in the number of T-cells producing proinflammatory cytokines, observed post extracorporeal photopheresis, is not purely linked to apoptosis induction
J. Bladon, P.C Taylor (Rotherham, UK)
Extracorporeal photopheresis (ECP) has been shown to be clinically effective in the treatment of Cutaneous T cell lymphoma (CTCL) and Graft versus host disease (GvHD). ECP therapy involves the exposure of cells, separated by leucopheresis, to 8 Methoxypsoralen (8-MOP) and UVA light. The treated cells are subsequently re-infused. Immediately following ECP a significant number of exposed lymphocytes become apoptotic. At this same time point, we recently determined that the number of T cells producing proinflammatory cytokines was reduced. This study sought to determine if the down-regulation of cytokine expression was a direct consequence o f apoptosis. Samples were taken from 6 GvHD and 5 CTCL patients immediately pre ECP and from the leucocyte collection bag prior to re-infusion. PBMC's were placed in cell culture and stimulated with PMA, Ionomycin and Brefaldin A for 6 hrs. Using flow cytometry, T cells were identified by CD3 expression, sub selection of the apoptotic T cells utilised annexin V attachment. Both apoptotic and non-apoptotic populations were evaluated for intracellular expression of IL2, IL4, IL10, IFNgamma and TNF-alpha. Neither patient group demonstrated any significant change in IL4 or IL10 expression within the apoptotic and non-apoptotic T cell populations post ECP. However the number of T cells expressing IL2, IFN-gamma and TNF-alpha was reduced for both T cell populations (p<0.05). Comparisons for each cytokine demonstrated the largest decrease to occur within the apoptotic population. The cytokine expression post ECP, as a percentage of pre ECP, fell between 42 and 78%. Down-regulation of each cytokine within the annexin-V negative T cells was also profound, ranging from 29 to 57%. GvHD patients demonstrated the largest reduction in cytokine expression, within the non-apoptotic T cell population, for all three cytokines and the biggest fall in the number of apoptotic T cells expressing IL2. For IFN-gamma and TNF-alpha, results were comparable for both patient groups. Pro-inflammatory cytokines play a major role in the pathology of GvHD. ECP is capable of down-regulating expression of these cytokines very early in the treatment cycle. Although the apoptotic population seems most sensitive to this downregulatory process, the non-apoptotic T cells also demonstrate a marked reduction. However lack of an increase in IL4 and IL10 expression indicate that this process is not a consequence of skewing toward a Th2 cytokine profile.
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In vitro priming of HLA-identical T-cells with allogeneic dendritic cells allows identification of an MHC class IIrestricted minor H Ag peptide encoded by DBY D. Laurin, E. Spierings, Y. Bertrand, M. Vogt, J.H.F. Falkenburg, C. Vermeulen, C. Galambrun, G. Souillet, L. Gebuhrer, D. Rigal, E. Goulmy, A. Eljaafari (Lyon, F; Leiden, NL) Even following HLA-identical stem cell transplantation, graft versus host disease (GvHD) can occur. In this situation, recognition of foreign minor histocompatibility antigens (minor H Ag) by donor T cells is responsible for the disease. HLA-identical allogeneic T cell responses can be induced in vitro using dendritic cells. In this way, T cell clones specific for an H-Y minor H Ag associated with HLA-DQ beta1*0502 have been isolated. (Transplantation, 2001 (Transplantation, , 71: 1449 . Using HLA-DQ beta1*0502-expressing female B EBV-LCL transfected with various H -Y genes, we here show that these T cell clones are specific for a peptide encoded by DBY The same peptide was also recognized by an HLA-DQ beta1*0501-restricted H-Y specific T cell clone This T cell clone was generated in vitro from another HLAidentical sibling pair. The peptide corresponds to the epitope of a T cell clone isolated in vivo from a patient suffering from GvHD (M Vogt et al Blood, 2002 99:3027) . Both the DQ beta1*0501-and the DQ beta1*0502-restricted H-Y specific T cell clones used the same V beta gene rearrangement. In conclusion, our results demonstrate that in vitro priming of HLA-identical T cells with dendritic cells can result in the isolation and characterization of minor H peptide. Moreover, these results suggest that this methodology could favour the isolation of immunodominant HLA-class II-associated minor H Ag. This work was supported by the Association de Recherche Contre le Cancer
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Factors affecting peripheral blood progenitor cell mobilization and harvesting in the autotransplant setting: a GITMO (Gruppo Italiano Trapianto Midollo Osseo) retrospective study on 1,907 mobilization procedures C. Tarella, F. Pompei, L. Cavazzuti, F. Marmont, A. Bacigalupo, G 
. Arcese on behalf of the GITMO (Gruppo Italiano Trapianto Midollo Osseo)
PBPC mobilization and harvesting is a widely employed procedure in the autotransplant setting. In order to investigate the factors influencing the extent of PBPC mobilization, data were collected from 1,907 procedures performed by 49 Centers associated to the GITMO during the year 1999. Patients had a median age of 47y, their diagnosis was: acute myeloblastic leukemia (AML) (226pts, 11.8%), acute lymphoblastic leukemia (76pts, 4%), non-Hodgkin's lymphoma (572pts, 30%), Hodgkin's Lymphoma (44pts., 7.6%), multiple myeloma (385pts., 20.2%), solid tumor (424pts., 22.2%), non-malignant disease (80pts, 4.2%). The mobilizing treatment was part of the front-line induction therapy in 1,336pts (70.4%), whereas 560pts (29.3%) underwent mobilization for refractory or relapsed disease. Mobilization was induced by G-CSF + chemotherapy at highdose (hd) in 1,078pts (56.5%) or at conventional dose in 609pts (31.9%), or by G -CSF alone in 206pts (10.8%) (other procedures: 0.7%). When combined with chemotherapy, G-CSF was employed at 5 mcgr/kg/day in 1,277pts (76%) or at higher doses in 405pts (24%). According to the total collected CD34+ve
